Caris Life Sciences, Inc. Cash Flow Statement
CAI / Health Care|3 years of annual SEC 10-K data (FY2023-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 3 fiscal years. All figures from audited SEC 10-K filings.
Caris Life Sciences, Inc. generated $83M in operating cash flow and $67M in free cash flow in FY2025. Free cash flow margin was 8.2% of revenue.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -0.08 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Net Income | -$68.1M | -$281.9M | -$341.4M |
| Depreciation & Amortization | $22.6M | $48.9M | $49.0M |
| Operating Cash Flow | $83.2M | -$245.2M | -$276.1M |
| Capital Expenditures | $16.3M | $8.4M | $22.3M |
| Free Cash Flow | $66.9M | -$253.6M | -$298.4M |
| Share Buybacks | $113.0K | $0 | $0 |
| FCF Margin | 8.2% | -61.5% | -97.5% |